Trial Profile
A Phase IIIB, Randomized, Open-Label, Parallel Group, Multi-Center, Non-Inferiority, 24-Week Study to Evaluate the Safety, Efficacy and Tolerability of Switching From a 200mg Ritonavir-Boosted Regimen of LEXIVA (700mg/100mg BID or 1400mg/200mg QD) to a Once-Daily, 100mg Ritonavir-Boosted Regimen of LEXIVA (1400mg/100mg QD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Jun 2023
Price :
$35
*
At a glance
- Drugs Fosamprenavir (Primary) ; Ritonavir (Primary) ; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms LESS
- Sponsors GlaxoSmithKline; GSK
- 24 Feb 2009 Actual patient numbers (211) added as reported by ClinicalTrials.gov.
- 22 Nov 2008 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.
- 16 May 2008 The expected completion date for this trial is now 1 Jan 2008.